Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
COVID-19 vaccine decisions: considering the choices and opportunities.
Microbes Infect
July 2021
Department of Health Promotion and Community Health Sciences, Texas A&M School of Public Health, College Station, TX, USA.
In the coming months, most American adults will have the opportunity to receive at least one of up to five different COVID-19 vaccines produced by Operation Warp Speed and released through emergency use authorization by the U.S. Food and Drug Administration (FDA).
View Article and Find Full Text PDFAmerica's deadly flirtation with antiscience and the medical freedom movement.
J Clin Invest
April 2021
Department of Pediatrics and Department of Molecular Virology & Microbiology, Texas Children's Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.
Pharmacoeconomics
December 2020
Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.
Recently licensed cell and gene therapies have promising but highly uncertain clinical benefits. They are entering the market at very high prices, with the latest entrants costing hundreds of thousands of dollars. The significant long-term uncertainty posed by these therapies has already complicated the use of conventional economic evaluation approaches such as cost-effectiveness and cost-utility analyses, which are widely used for assessing the value of new health interventions.
View Article and Find Full Text PDFRisks and management of antiepileptic drug induced skin reactions in the adult out-patient setting.
Seizure
November 2019
St George's University Medical School, United Kingdom; St George's Univ. Hospital NHS Foundation Trust, United Kingdom.
Adverse cutaneous reactions caused by mostly aromatic antiepileptic drugs (AED) affect 50.000 people a year in the United Kingdom (UK; incidence 75.7/100.
View Article and Find Full Text PDFSocietal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
Value Health
May 2018
Centre for Health Economics and Medicines Evaluation, Ardudwy, Normal Site, Bangor University, Holyhead Road, Bangor, Gwynedd, LL57 2PZ, UK. Electronic address:
Background: It is unclear whether UK National Health Service (NHS) policies for orphan drugs, which permit funding of non-cost-effective treatments, reflect societal preferences.
Methods: We conducted person trade-off (PTO) and discrete choice experiment (DCE) among 3950 adults selected to be representative of the UK general population. Experimental design was informed by surveys of patients affected by rare diseases, their caregivers, health care staff, and policymakers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!